Breast cancer classification (English Wikipedia)

Percentage values are from United States statistics 2004. Subtype specific incidences are taken from Table 6 Archived 23 February 2013 at archive.today (invasive) and Table 3 Archived 23 February 2013 at archive.today (in situ) from Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC (June 2009). "The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004". Cancer Epidemiol. Biomarkers Prev. 18 (6): 1763–9. doi:10.1158/1055-9965.EPI-08-1082. PMID 19454615.. These are divided by total breast cancer incidence (211,300 invasive and 55,700 in situ cases) as reported from Breast Cancer Facts & Figures 2003–2004 "ACS :: Breast Cancer Facts & Figures 2003-2004". Archived from the original on 15 April 2009. Retrieved 15 June 2010.

abstracts2view.com (Global: low place; English: low place)

Rae, JM; Drury, S; Hayes, DF; et al. (9 December 2010). "Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial. 33rd Annual San Antonio Breast Cancer Symposium (SABCS): abstract S1-7". Archived from the original on 11 August 2011. Retrieved 17 December 2010.
Leyland-Jones, B; Regan, MM; Bouzyk, M; et al. (9 December 2010). "Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial. 33rd Annual San Antonio Breast Cancer Symposium (SABCS): abstract S1-8". Archived from the original on 7 July 2011. Retrieved 17 December 2010.

agendia.com (Global: low place; English: low place)

The mission of Agendia. Agendia web isite.http://www.agendia.com/pages/mission/86.php Archived 23 November 2013 at the Wayback Machine
Ordering Symphony is a simple process. Agendia web site.http://www.agendia.com/pages/ordering_symphony/38.php Archived 5 June 2011 at the Wayback Machine
MammaPrint Patient Eligibility Internationally (Outside of the USA) http://www.agendia.com/pages/patient_eligibility_internationally/317.php Archived 5 June 2011 at the Wayback Machine
Introducing BluePrint: A Molecular Subtyping Profile for Breast Cancer. Agendia web site.http://www.agendia.com/pages/blueprint/324.php Archived 3 September 2011 at the Wayback Machine

archive.org (Global: 6^th place; English: 6^th place)

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007). "Overview of Resistance to Systemic Therapy in Patients with Breast Cancer". In Yu D, Hung MC (eds.). Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology. Vol. 608. pp. 1–22. doi:10.1007/978-0-387-74039-3_1. ISBN 978-0-387-74037-9. PMID 17993229.

archive.today (Global: 14^th place; English: 14^th place)

Percentage values are from United States statistics 2004. Subtype specific incidences are taken from Table 6 Archived 23 February 2013 at archive.today (invasive) and Table 3 Archived 23 February 2013 at archive.today (in situ) from Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC (June 2009). "The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004". Cancer Epidemiol. Biomarkers Prev. 18 (6): 1763–9. doi:10.1158/1055-9965.EPI-08-1082. PMID 19454615.. These are divided by total breast cancer incidence (211,300 invasive and 55,700 in situ cases) as reported from Breast Cancer Facts & Figures 2003–2004 "ACS :: Breast Cancer Facts & Figures 2003-2004". Archived from the original on 15 April 2009. Retrieved 15 June 2010.

books.google.com (Global: 3^rd place; English: 3^rd place)

Page 1084 Archived 6 August 2022 at the Wayback Machine in: Robbins, Stanley (2010). Robbins and Cotran pathologic basis of disease. Philadelphia, PA: Saunders/Elsevier. ISBN 978-1-4377-2182-9. OCLC 489074868.

breast-cancer-research.com (Global: low place; English: low place)

Evans, A. (2004). "Ductal carcinoma in situ (DCIS): are we overdetecting it?". Breast Cancer Research. 6 (Suppl 1) P23: 23. doi:10.1186/bcr842. PMC 3300383. [1] Archived 8 July 2011 at the Wayback Machine

cancer.gov (Global: 1,684^th place; English: 1,350^th place)

National Cancer Institute. Stage Information for Breast Cancer.http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional/page3 Archived 8 June 2011 at the Wayback Machine
NCI Cancer Bulletin FDA Update 2007 February 14, Volume 4, Number 7 as Retrieved 17 October 2010 at http://www.cancer.gov/aboutnci/ncicancerbulletin/archive/2007/021407/page5 Archived 22 December 2010 at the Wayback Machine

cancer.org (Global: 3,680^th place; English: 2,918^th place)

Percentage values are from United States statistics 2004. Subtype specific incidences are taken from Table 6 Archived 23 February 2013 at archive.today (invasive) and Table 3 Archived 23 February 2013 at archive.today (in situ) from Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC (June 2009). "The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004". Cancer Epidemiol. Biomarkers Prev. 18 (6): 1763–9. doi:10.1158/1055-9965.EPI-08-1082. PMID 19454615.. These are divided by total breast cancer incidence (211,300 invasive and 55,700 in situ cases) as reported from Breast Cancer Facts & Figures 2003–2004 "ACS :: Breast Cancer Facts & Figures 2003-2004". Archived from the original on 15 April 2009. Retrieved 15 June 2010.

cancernetwork.com (Global: low place; English: low place)

"Understanding and Treating Triple-Negative Breast Cancer". Cancer Network. Archived from the original on 9 June 2010. Retrieved 8 May 2010.

cancerstaging.org (Global: low place; English: low place)

What is Cancer Staging? American Joint Committee on Cancer 2010 May 5.http://www.cancerstaging.org/mission/whatis.html Archived 27 August 2013 at the Wayback Machine
American Joint Committee on Cancer. Past Editions of the AJCC Cancer Staging Manual available at "American Joint Committee on Cancer: Publications & Electronic Products: Past Editions of the AJCC Cancer Staging Manual". Archived from the original on 6 January 2011. Retrieved 3 January 2011.
AJCC Cancer Staging Manual, 7th edition, updated Cancer Staging Posters.http://www.cancerstaging.org/staging/posters/breast8.5x11.pdf Archived 26 June 2011 at the Wayback Machine
AJCC Cancer Staging Manual 6th edition; Chapter 25; Breast Cancer – original pages 223-240 http://www.cancerstaging.org/products/csmanual6ed-4.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 5th edition; Chapter 25; Breast Cancer – original pages 171-180 http://www.cancerstaging.org/products/csmanual5ed_4.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 4th edition; Chapter 25; Breast Cancer – original pages 149-154 http://www.cancerstaging.org/products/csmanual4ed_2.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 3rd edition; 1988; Chapter 23; Breast Cancer-original pages 145-150 http://www.cancerstaging.org/products/csmanual3ed_2.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 2nd edition; 1983; Chapter 21; Breast Cancer-original pages 127-134 http://www.cancerstaging.org/products/csmanual2ed.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 1977; Chapter 12; Breast Cancer-original pages 101-108 http://www.cancerstaging.org/products/csmanual1ed.pdf Archived 28 September 2011 at the Wayback Machine

creativecommons.org (Global: 1,010^th place; English: 612^th place)

Originally copied from Fadi M. Alkabban; Troy Ferguson (2021). "Breast Cancer". Cancer, Breast. StatPearls. PMID 29493913. Archived from the original on 24 December 2020. Retrieved 4 October 2019 – via National Center for Biotechnology Information. Last Update: 4 June 2019. Creative Commons Attribution 4.0 International License Archived 21 November 2015 at the Wayback Machine

ctaf.org (Global: low place; English: low place)

Tice JA. The 70-Gene Signature (MammaPrint) as a Guide for the Management of Early Stage Breast Cancer. California Technology Assessment Forum. 2010 June 2nd. Full text accessioned 2010 Dec 19 at http://www.ctaf.org/content/assessments/detail/?id=1178 Archived 25 July 2011 at the Wayback Machine

doi.org (Global: 2^nd place; English: 2^nd place)

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007). "Overview of Resistance to Systemic Therapy in Patients with Breast Cancer". In Yu D, Hung MC (eds.). Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology. Vol. 608. pp. 1–22. doi:10.1007/978-0-387-74039-3_1. ISBN 978-0-387-74037-9. PMID 17993229.
Giordano SH, Hortobagyi GN (2003). "Inflammatory breast cancer: Clinical progress and the main problems that must be addressed". Breast Cancer Res. 5 (6) 284: 284–8. doi:10.1186/bcr608. PMC 314400. PMID 14580242.
Ductal carcinoma in situ: 99% - Kerlikowske, K (2010). "Epidemiology of ductal carcinoma in situ". Journal of the National Cancer Institute. Monographs. 2010 (41): 139–41. doi:10.1093/jncimonographs/lgq027. PMC 5161058. PMID 20956818.
Lobular carcinoma in situ: 97% - Xie, Ze-Ming; Sun, Jian; Hu, Zhe-Yu; Wu, Yao-Pan; Liu, Peng; Tang, Jun; Xiao, Xiang-Sheng; Wei, Wei-Dong; Wang, Xi; Xie, Xiao-Ming; Yang, Ming-Tian (2017). "Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy". European Journal of Cancer. 82: 6–15. doi:10.1016/j.ejca.2017.05.030. ISSN 0959-8049. PMID 28646773.
Percentage values are from United States statistics 2004. Subtype specific incidences are taken from Table 6 Archived 23 February 2013 at archive.today (invasive) and Table 3 Archived 23 February 2013 at archive.today (in situ) from Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC (June 2009). "The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004". Cancer Epidemiol. Biomarkers Prev. 18 (6): 1763–9. doi:10.1158/1055-9965.EPI-08-1082. PMID 19454615.. These are divided by total breast cancer incidence (211,300 invasive and 55,700 in situ cases) as reported from Breast Cancer Facts & Figures 2003–2004 "ACS :: Breast Cancer Facts & Figures 2003-2004". Archived from the original on 15 April 2009. Retrieved 15 June 2010.
NOTE: Number really refers to invasive ductal carcinoma, despite title. Arpino G, Bardou VJ, Clark GM, Elledge RM (2004). "Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome". Breast Cancer Res. 6 (3) R149: R149–56. doi:10.1186/bcr767. PMC 400666. PMID 15084238.
Evans, A. (2004). "Ductal carcinoma in situ (DCIS): are we overdetecting it?". Breast Cancer Research. 6 (Suppl 1) P23: 23. doi:10.1186/bcr842. PMC 3300383. [1] Archived 8 July 2011 at the Wayback Machine
Elston, CW; Ellis, IO (1991). "Pathologic prognostic factors in breast cancer. I. The value of histological grades in breast cancer. Experience from a large study with long-term follow-up". Histopathology. 19 (5): 403–10. doi:10.1111/j.1365-2559.1991.tb00229.x. PMID 1757079. S2CID 17622089. "Republished". Histopathology. 41: 154–161. 2002. doi:10.1046/j.1365-2559.2002.14892.x. S2CID 208083532.
Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, et al. (December 2004). "Prognostic relevance of gene amplifications and coamplifications in breast cancer". Cancer Research. 64 (23): 8534–8540. doi:10.1158/0008-5472.CAN-04-1945. PMID 15574759.
Bloom, H.J.; Richardson, W.W. (1957). "Histological grading and prognosis in breast cancer; A study of 1409 cases of which 359 have been followed for 15 years". British Journal of Cancer. 11 (3): 359–77. doi:10.1038/bjc.1957.43. PMC 2073885. PMID 13499785.
Pujani, Mukta; Sharma, KiranLata; Srivastava, AN; Singh, US; Bansal, Cherry (2014). "Grading systems in the cytological diagnosis of breast cancer: A review". Journal of Cancer Research and Therapeutics. 10 (4): 839–845. doi:10.4103/0973-1482.140979. ISSN 0973-1482. PMID 25579516.
Scatarige JC, Fishman EK, Zinreich ES, Brem RF, Almaraz R (April 1988). "Internal mammary lymphadenopathy in breast carcinoma: CT appraisal of anatomic distribution". Radiology. 167 (1): 89–91. doi:10.1148/radiology.167.1.3347753. PMID 3347753.
Scatarige JC, Boxen I, Smathers RL (September 1990). "Internal mammary lymphadenopathy: imaging of a vital lymphatic pathway in breast cancer". Radiographics. 10 (5): 857–70. doi:10.1148/radiographics.10.5.2217975. PMID 2217975. available as full text article with multiple images at http://radiographics.rsna.org/content/10/5/857.full.pdf
Data from: Mangone L; Marinelli F; Bisceglia I; Braghiroli MB; Damato A; Pinto C (2022). "Five-year relative survival by stage of breast and colon cancers in northern Italy". Front Oncol. 12 982461. doi:10.3389/fonc.2022.982461. PMC 9659859. PMID 36387150.
Feinstein, A. R.; Sosin, D. M.; Wells, C. K. (1985). "The Will Rogers Phenomenon". New England Journal of Medicine. 312 (25): 1604–1608. doi:10.1056/NEJM198506203122504. PMID 4000199.
Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter NR, et al. (September 2003). "Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival". Journal of Clinical Oncology. 21 (17): 3244–3248. doi:10.1200/JCO.2003.03.052. PMID 12947058.
Sotirou Christos, Pusztai Lajos (2009). "Molecular origin of cancer: gene-expression signatures in breast cancer". The New England Journal of Medicine. 360 (8): 790–800. doi:10.1056/NEJMra0801289. PMID 19228622. Archived from the original on 5 January 2010. Retrieved 16 June 2010.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. (October 2005). "Trastuzumab plus adjuvant chemotherapy for operable HER2+ breast cancer". The New England Journal of Medicine. 353 (16): 1673–1684. doi:10.1056/NEJMoa052122. PMID 16236738. S2CID 9534884.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. (August 2007). "Triple-negative breast cancer: clinical features and patterns of recurrence". Clinical Cancer Research. 13 (15 Pt 1): 4429–4434. doi:10.1158/1078-0432.CCR-06-3045. PMID 17671126.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. (July 2011). "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies". Journal of Clinical Investigation. 121 (7): 2750–2767. doi:10.1172/JCI45014. PMC 3127435. PMID 21633166.
Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, et al. (2011). "Androgen receptor expression and breast cancer survival in postmenopausal women". Clinical Cancer Research. 17 (7): 1867–1874. doi:10.1158/1078-0432.CCR-10-2021. PMC 3076683. PMID 21325075.
Prat, A.; Perou, C. M. (2011). "Deconstructing the molecular portraits of breast cancer". Molecular Oncology. 5 (1): 5–23. doi:10.1016/j.molonc.2010.11.003. PMC 5528267. PMID 21147047.
Geyer, F. C.; Marchiò, C.; Reis-Filho, J. S. (2009). "The role of molecular analysis in breast cancer". Pathology. 41 (1): 77–88. doi:10.1080/00313020802563536. PMID 19089743. S2CID 39374813.
Perou, C. M. (2011). "Molecular Stratification of Triple-Negative Breast Cancers". The Oncologist. 16: 61–70. doi:10.1634/theoncologist.2011-S1-61. PMID 21278442.
Ross, J. S. (2009). "Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome". Advances in Anatomic Pathology. 16 (4): 204–215. doi:10.1097/PAP.0b013e3181a9d4bf. PMID 19546609. S2CID 37465636.
Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. (February 2012). "Breast Cancer Special Feature: Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells". Proceedings of the National Academy of Sciences. 109 (8): 2778–2783. doi:10.1073/pnas.1018862108. PMC 3286979. PMID 21633010.
Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. (April 2012). "Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse". Breast Cancer Research and Treatment. 132 (2): 523–535. doi:10.1007/s10549-011-1619-7. PMC 3303043. PMID 21671017.
Tsang, Julia Y.S.; Tse, Gary M. (2020). "Molecular Classification of Breast Cancer". Advances in Anatomic Pathology. 27 (1): 27–35. doi:10.1097/PAP.0000000000000232. ISSN 1072-4109. PMID 31045583. S2CID 143423297.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. (August 2000). "Molecular portraits of human breast tumours". Nature. 406 (6797): 747–752. Bibcode:2000Natur.406..747P. doi:10.1038/35021093. PMID 10963602. S2CID 1280204.
Nagasaki K, Miki Y (2006). "Gene expression profiling of breast cancer". Breast Cancer. 13 (1): 2–7. doi:10.2325/jbcs.13.2. PMID 16518056. S2CID 6255927.
Normanno N, De Luca A, Carotenuto P, Lamura L, Oliva I, D'Alessio A (2009). "Prognostic applications of gene expression signatures in breast cancer". Oncology. 77 (Suppl 1): 2–8. doi:10.1159/000258489. PMID 20130425. S2CID 21011879.
Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, et al. (2010). "Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics". Breast Cancer Research. 12 (3) R42. doi:10.1186/bcr2596. PMC 2917037. PMID 20576095.
Sparano JA, Solin LJ (April 2010). "Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making". Journal of Clinical Oncology. 28 (10): 1625–7. doi:10.1200/JCO.2009.25.2882. PMID 20065178.
Mandrekar SJ, Sargent DJ (October 2010). "Predictive biomarker validation in practice: lessons from real trials". Clin Trials. 7 (5): 567–73. doi:10.1177/1740774510368574. PMC 3913192. PMID 20392785.
Pharoah PD, Caldas C (November 2010). "Genetics: How to validate a breast cancer prognostic signature". Nat Rev Clin Oncol. 7 (11): 615–6. doi:10.1038/nrclinonc.2010.142. PMID 20981123. S2CID 32411967.
Ross, J. S.; Hatzis, C.; Symmans, W. F.; Pusztai, L.; Hortobagyi, G. N. (2008). "Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer". The Oncologist. 13 (5): 477–493. doi:10.1634/theoncologist.2007-0248. PMID 18515733. S2CID 19435207.
Albain, K. S.; Paik, S.; Van't Veer, L. (2009). "Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays". The Breast. 18: S141–S145. doi:10.1016/S0960-9776(09)70290-5. PMID 19914534.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. (August 2006). "Concordance among gene-expression-based predictors for breast cancer". New England Journal of Medicine. 355 (6): 560–569. doi:10.1056/NEJMoa052933. PMID 16899776.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. (((American Society of Clinical Oncology))) (November 2007). "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer". Journal of Clinical Oncology. 25 (33): 5287–5312. doi:10.1200/JCO.2007.14.2364. PMC 2793754. PMID 17954709.
Filho, O. M.; Ignatiadis, M.; Sotiriou, C. (2011). "Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis". Critical Reviews in Oncology/Hematology. 77 (1): 20–29. doi:10.1016/j.critrevonc.2010.01.011. PMID 20138540.
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. (October 2005). "Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer". Journal of Clinical Oncology. 23 (29): 7265–7277. doi:10.1200/JCO.2005.02.0818. PMID 16145055.
Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, et al. (November 2010). "Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers". Cancer. 116 (22): 5161–5167. doi:10.1002/cncr.25269. PMID 20665886.
Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, et al. (April 2010). "Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection". Journal of Clinical Oncology. 28 (10): 1671–1676. doi:10.1200/JCO.2008.20.2119. PMID 20065191.
Albanell, J.; González, A.; Ruiz-Borrego, M.; Alba, E.; García-Saenz, J. A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limon, M. L.; Muñoz, A. S.; Martín, M.; Tusquets, I.; Rojo, F.; Colomer, R.; Faull, I.; Lluch, A. (2011). "Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer". Annals of Oncology. 23 (3): 625–631. doi:10.1093/annonc/mdr278. hdl:10630/29523. PMID 21652577.
MacGrogan G, Rudolph P, Mascarel I, Mauriac L, Durand M, Avril A, et al. (August 2003). "DNA topoisomerase II alfa expression and the response to primary chemotherapy in breast cancer". British Journal of Cancer. 89 (4): 666–671. doi:10.1038/sj.bjc.6601185. PMC 2376904. PMID 12915875.
Alvarez, R. H.; Valero, V.; Hortobagyi, G. N. (2010). "Emerging Targeted Therapies for Breast Cancer". Journal of Clinical Oncology. 28 (20): 3366–3379. doi:10.1200/JCO.2009.25.4011. PMID 20530283.
Issaeva N, Thomas HD, Djureinovic T, Djurenovic T, Jaspers JE, Stoimenov I, et al. (August 2010). "6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance". Cancer Research. 70 (15): 6268–6276. doi:10.1158/0008-5472.CAN-09-3416. PMC 2913123. PMID 20631063. Correction published at Correction: 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance Cancer Res 2010 October 1;70:7734
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. (June 2009). "Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer". Journal of Clinical Oncology. 27 (16): 2630–2637. doi:10.1200/JCO.2008.18.8391. PMID 19380449.
D'Anello L, Sansone P, Storci G, Mitrugno V, D'Uva G, Chieco P, et al. (November 2010). "Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells". Molecular Cancer. 9 300. doi:10.1186/1476-4598-9-300. PMC 3002335. PMID 21092249.
Liu, C. -C.; Prior, J.; Piwnica-Worms, D.; Bu, G. (2010). "LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy". Proceedings of the National Academy of Sciences. 107 (11): 5136–5141. Bibcode:2010PNAS..107.5136L. doi:10.1073/pnas.0911220107. PMC 2841938. PMID 20194742.
Ruiter R, Bijl MJ, van Schaik RH, Berns EM, Hofman A, Coebergh JW, et al. (October 2010). "CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen". Pharmacogenomics. 11 (10): 1367–1375. doi:10.2217/pgs.10.112. PMID 21047200.
Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjöld B, Stål O (2010). "Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer". Breast Cancer Research. 12 (4) R53: 206. doi:10.1186/bcr2612. PMC 2949642. PMID 20649975.
"Study sheds new light on tamoxifen resistance". CORDIS : News. 13 November 2008. Archived from the original on 20 February 2009. Retrieved 14 November 2008.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. (December 2008). "Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen". Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.
Mc Ilroy M, Fleming FJ, Buggy Y, Hill AD, Young LS (December 2006). "Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence". Endocr. Relat. Cancer. 13 (4): 1135–45. doi:10.1677/erc.1.01222. PMID 17158759.
Spears M, Bartlett J (June 2009). "The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer". Expert Opin. Ther. Targets. 13 (6): 665–74. doi:10.1517/14728220902911509. PMID 19456271. S2CID 39034059.
Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. (February 2001). "Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer". Journal of Clinical Oncology. 19 (4): 980–991. doi:10.1200/JCO.2001.19.4.980. PMID 11181660.
Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. (April 2005). "Population-based validation of the prognostic model ADJUVANT! for early breast cancer". Journal of Clinical Oncology. 23 (12): 2716–2725. doi:10.1200/JCO.2005.06.178. PMID 15837986. S2CID 27080534.
Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, et al. (November 2009). "Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study". Lancet Oncology. 10 (11): 1070–1076. doi:10.1016/S1470-2045(09)70254-2. PMID 19801202.
Campbell HE, Taylor MA, Harris AL, Gray AM (October 2009). "An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom". Br. J. Cancer. 101 (7): 1074–84. doi:10.1038/sj.bjc.6605283. PMC 2768087. PMID 19724274.
Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. (2010). "PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer". Breast Cancer Research. 12 (1) R1. doi:10.1186/bcr2464. PMC 2880419. PMID 20053270.
Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. (August 2010). "BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received". British Journal of Cancer. 103 (5): 668–75. doi:10.1038/sj.bjc.6605736. PMC 2938244. PMID 20664598.
Silverstein Melvin J., Lagios Michael D. (2010). "Choosing Treatment for Patients With Ductal Carcinoma In Situ: Fine Tuning the University of Southern California/Van Nuys Prognostic Index". J Natl Cancer Inst Monogr. 2010 (41): 193–196. doi:10.1093/jncimonographs/lgq040. PMC 5161065. PMID 20956828.

emaxhealth.com (Global: low place; English: low place)

Armen Hareyanon. MapQuant Dx Genomic Grade Test Identifies Breast Cancer Patients. 2 June 2008 http://www.emaxhealth.com/98/22731.html Archived 29 September 2011 at the Wayback Machine

europa.eu (Global: 68^th place; English: 117^th place)

cordis.europa.eu

"Study sheds new light on tamoxifen resistance". CORDIS : News. 13 November 2008. Archived from the original on 20 February 2009. Retrieved 14 November 2008.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. (December 2008). "Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen". Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.

fda.gov (Global: 447^th place; English: 338^th place)

"FDA Approves First Targeted Therapy for HER2-Low Breast Cancer". U.S. Food and Drug Administration (FDA) (Press release). 5 August 2022. Archived from the original on 6 August 2022. Retrieved 5 August 2022. This article incorporates text from this source, which is in the public domain.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

Albanell, J.; González, A.; Ruiz-Borrego, M.; Alba, E.; García-Saenz, J. A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limon, M. L.; Muñoz, A. S.; Martín, M.; Tusquets, I.; Rojo, F.; Colomer, R.; Faull, I.; Lluch, A. (2011). "Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer". Annals of Oncology. 23 (3): 625–631. doi:10.1093/annonc/mdr278. hdl:10630/29523. PMID 21652577.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. (August 2000). "Molecular portraits of human breast tumours". Nature. 406 (6797): 747–752. Bibcode:2000Natur.406..747P. doi:10.1038/35021093. PMID 10963602. S2CID 1280204.
Liu, C. -C.; Prior, J.; Piwnica-Worms, D.; Bu, G. (2010). "LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy". Proceedings of the National Academy of Sciences. 107 (11): 5136–5141. Bibcode:2010PNAS..107.5136L. doi:10.1073/pnas.0911220107. PMC 2841938. PMID 20194742.
"Study sheds new light on tamoxifen resistance". CORDIS : News. 13 November 2008. Archived from the original on 20 February 2009. Retrieved 14 November 2008.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. (December 2008). "Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen". Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.

ipsogen.com (Global: low place; English: low place)

"Select your country: Qiagen Marseille" (PDF). ipsogen.com. Archived from the original (PDF) on 26 March 2012. Retrieved 12 December 2015.

medscape.com (Global: 719^th place; English: 636^th place)

medscape.com

Oudai Hassan. "What is the Nottingham combined histologic grade (modified Scarff-Bloom-Richardson grade) system for breast tumors?". Medscape. Archived from the original on 30 November 2020. Retrieved 2 October 2019. Updated: 20 March 2019

emedicine.medscape.com

Joseph A Sparano, MD (6 October 2021). "Breast Cancer Staging". medscape. Archived from the original on 13 September 2020. Retrieved 21 August 2020. Updated: 8 June 2019

merck.com (Global: 6,464^th place; English: 5,671^st place)

Merck Manual, Professional Edition Archived 1 July 2010 at the Wayback Machine, Ch. 253, Breast Cancer.

nccn.org (Global: low place; English: low place)

"National Comprehensive Cancer Network (NCCN) guidelines, Breast Cancer Version 2.2011" (PDF). Archived (PDF) from the original on 24 March 2009. Retrieved 3 July 2011.

nejm.org (Global: 2,374^th place; English: 6,027^th place)

content.nejm.org

Sotirou Christos, Pusztai Lajos (2009). "Molecular origin of cancer: gene-expression signatures in breast cancer". The New England Journal of Medicine. 360 (8): 790–800. doi:10.1056/NEJMra0801289. PMID 19228622. Archived from the original on 5 January 2010. Retrieved 16 June 2010.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007). "Overview of Resistance to Systemic Therapy in Patients with Breast Cancer". In Yu D, Hung MC (eds.). Breast Cancer Chemosensitivity. Advances in Experimental Medicine and Biology. Vol. 608. pp. 1–22. doi:10.1007/978-0-387-74039-3_1. ISBN 978-0-387-74037-9. PMID 17993229.
Giordano SH, Hortobagyi GN (2003). "Inflammatory breast cancer: Clinical progress and the main problems that must be addressed". Breast Cancer Res. 5 (6) 284: 284–8. doi:10.1186/bcr608. PMC 314400. PMID 14580242.
Ductal carcinoma in situ: 99% - Kerlikowske, K (2010). "Epidemiology of ductal carcinoma in situ". Journal of the National Cancer Institute. Monographs. 2010 (41): 139–41. doi:10.1093/jncimonographs/lgq027. PMC 5161058. PMID 20956818.
Lobular carcinoma in situ: 97% - Xie, Ze-Ming; Sun, Jian; Hu, Zhe-Yu; Wu, Yao-Pan; Liu, Peng; Tang, Jun; Xiao, Xiang-Sheng; Wei, Wei-Dong; Wang, Xi; Xie, Xiao-Ming; Yang, Ming-Tian (2017). "Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy". European Journal of Cancer. 82: 6–15. doi:10.1016/j.ejca.2017.05.030. ISSN 0959-8049. PMID 28646773.
Percentage values are from United States statistics 2004. Subtype specific incidences are taken from Table 6 Archived 23 February 2013 at archive.today (invasive) and Table 3 Archived 23 February 2013 at archive.today (in situ) from Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC (June 2009). "The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004". Cancer Epidemiol. Biomarkers Prev. 18 (6): 1763–9. doi:10.1158/1055-9965.EPI-08-1082. PMID 19454615.. These are divided by total breast cancer incidence (211,300 invasive and 55,700 in situ cases) as reported from Breast Cancer Facts & Figures 2003–2004 "ACS :: Breast Cancer Facts & Figures 2003-2004". Archived from the original on 15 April 2009. Retrieved 15 June 2010.
NOTE: Number really refers to invasive ductal carcinoma, despite title. Arpino G, Bardou VJ, Clark GM, Elledge RM (2004). "Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome". Breast Cancer Res. 6 (3) R149: R149–56. doi:10.1186/bcr767. PMC 400666. PMID 15084238.
Elston, CW; Ellis, IO (1991). "Pathologic prognostic factors in breast cancer. I. The value of histological grades in breast cancer. Experience from a large study with long-term follow-up". Histopathology. 19 (5): 403–10. doi:10.1111/j.1365-2559.1991.tb00229.x. PMID 1757079. S2CID 17622089. "Republished". Histopathology. 41: 154–161. 2002. doi:10.1046/j.1365-2559.2002.14892.x. S2CID 208083532.
Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, et al. (December 2004). "Prognostic relevance of gene amplifications and coamplifications in breast cancer". Cancer Research. 64 (23): 8534–8540. doi:10.1158/0008-5472.CAN-04-1945. PMID 15574759.
Bloom, H.J.; Richardson, W.W. (1957). "Histological grading and prognosis in breast cancer; A study of 1409 cases of which 359 have been followed for 15 years". British Journal of Cancer. 11 (3): 359–77. doi:10.1038/bjc.1957.43. PMC 2073885. PMID 13499785.
Genestie C, Zafrani B, Asselain B, Fourquet A, Rozan S, Validire P, et al. (1998). "Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: Major importance of the mitotic count as a component of both grading systems". Anticancer Research. 18 (1B): 571–6. PMID 9568179.
Pujani, Mukta; Sharma, KiranLata; Srivastava, AN; Singh, US; Bansal, Cherry (2014). "Grading systems in the cytological diagnosis of breast cancer: A review". Journal of Cancer Research and Therapeutics. 10 (4): 839–845. doi:10.4103/0973-1482.140979. ISSN 0973-1482. PMID 25579516.
Originally copied from Fadi M. Alkabban; Troy Ferguson (2021). "Breast Cancer". Cancer, Breast. StatPearls. PMID 29493913. Archived from the original on 24 December 2020. Retrieved 4 October 2019 – via National Center for Biotechnology Information. Last Update: 4 June 2019. Creative Commons Attribution 4.0 International License Archived 21 November 2015 at the Wayback Machine
Scatarige JC, Fishman EK, Zinreich ES, Brem RF, Almaraz R (April 1988). "Internal mammary lymphadenopathy in breast carcinoma: CT appraisal of anatomic distribution". Radiology. 167 (1): 89–91. doi:10.1148/radiology.167.1.3347753. PMID 3347753.
Scatarige JC, Boxen I, Smathers RL (September 1990). "Internal mammary lymphadenopathy: imaging of a vital lymphatic pathway in breast cancer". Radiographics. 10 (5): 857–70. doi:10.1148/radiographics.10.5.2217975. PMID 2217975. available as full text article with multiple images at http://radiographics.rsna.org/content/10/5/857.full.pdf
Data from: Mangone L; Marinelli F; Bisceglia I; Braghiroli MB; Damato A; Pinto C (2022). "Five-year relative survival by stage of breast and colon cancers in northern Italy". Front Oncol. 12 982461. doi:10.3389/fonc.2022.982461. PMC 9659859. PMID 36387150.
Feinstein, A. R.; Sosin, D. M.; Wells, C. K. (1985). "The Will Rogers Phenomenon". New England Journal of Medicine. 312 (25): 1604–1608. doi:10.1056/NEJM198506203122504. PMID 4000199.
Woodward WA, Strom EA, Tucker SL, McNeese MD, Perkins GH, Schechter NR, et al. (September 2003). "Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival". Journal of Clinical Oncology. 21 (17): 3244–3248. doi:10.1200/JCO.2003.03.052. PMID 12947058.
Sotirou Christos, Pusztai Lajos (2009). "Molecular origin of cancer: gene-expression signatures in breast cancer". The New England Journal of Medicine. 360 (8): 790–800. doi:10.1056/NEJMra0801289. PMID 19228622. Archived from the original on 5 January 2010. Retrieved 16 June 2010.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. (October 2005). "Trastuzumab plus adjuvant chemotherapy for operable HER2+ breast cancer". The New England Journal of Medicine. 353 (16): 1673–1684. doi:10.1056/NEJMoa052122. PMID 16236738. S2CID 9534884.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. (August 2007). "Triple-negative breast cancer: clinical features and patterns of recurrence". Clinical Cancer Research. 13 (15 Pt 1): 4429–4434. doi:10.1158/1078-0432.CCR-06-3045. PMID 17671126.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. (July 2011). "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies". Journal of Clinical Investigation. 121 (7): 2750–2767. doi:10.1172/JCI45014. PMC 3127435. PMID 21633166.
Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, et al. (2011). "Androgen receptor expression and breast cancer survival in postmenopausal women". Clinical Cancer Research. 17 (7): 1867–1874. doi:10.1158/1078-0432.CCR-10-2021. PMC 3076683. PMID 21325075.
Prat, A.; Perou, C. M. (2011). "Deconstructing the molecular portraits of breast cancer". Molecular Oncology. 5 (1): 5–23. doi:10.1016/j.molonc.2010.11.003. PMC 5528267. PMID 21147047.
Geyer, F. C.; Marchiò, C.; Reis-Filho, J. S. (2009). "The role of molecular analysis in breast cancer". Pathology. 41 (1): 77–88. doi:10.1080/00313020802563536. PMID 19089743. S2CID 39374813.
Perou, C. M. (2011). "Molecular Stratification of Triple-Negative Breast Cancers". The Oncologist. 16: 61–70. doi:10.1634/theoncologist.2011-S1-61. PMID 21278442.
Ross, J. S. (2009). "Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome". Advances in Anatomic Pathology. 16 (4): 204–215. doi:10.1097/PAP.0b013e3181a9d4bf. PMID 19546609. S2CID 37465636.
Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. (February 2012). "Breast Cancer Special Feature: Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells". Proceedings of the National Academy of Sciences. 109 (8): 2778–2783. doi:10.1073/pnas.1018862108. PMC 3286979. PMID 21633010.
Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. (April 2012). "Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse". Breast Cancer Research and Treatment. 132 (2): 523–535. doi:10.1007/s10549-011-1619-7. PMC 3303043. PMID 21671017.
Tsang, Julia Y.S.; Tse, Gary M. (2020). "Molecular Classification of Breast Cancer". Advances in Anatomic Pathology. 27 (1): 27–35. doi:10.1097/PAP.0000000000000232. ISSN 1072-4109. PMID 31045583. S2CID 143423297.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. (August 2000). "Molecular portraits of human breast tumours". Nature. 406 (6797): 747–752. Bibcode:2000Natur.406..747P. doi:10.1038/35021093. PMID 10963602. S2CID 1280204.
Nagasaki K, Miki Y (2006). "Gene expression profiling of breast cancer". Breast Cancer. 13 (1): 2–7. doi:10.2325/jbcs.13.2. PMID 16518056. S2CID 6255927.
Normanno N, De Luca A, Carotenuto P, Lamura L, Oliva I, D'Alessio A (2009). "Prognostic applications of gene expression signatures in breast cancer". Oncology. 77 (Suppl 1): 2–8. doi:10.1159/000258489. PMID 20130425. S2CID 21011879.
Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, et al. (2010). "Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics". Breast Cancer Research. 12 (3) R42. doi:10.1186/bcr2596. PMC 2917037. PMID 20576095.
Sparano JA, Solin LJ (April 2010). "Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making". Journal of Clinical Oncology. 28 (10): 1625–7. doi:10.1200/JCO.2009.25.2882. PMID 20065178.
Mandrekar SJ, Sargent DJ (October 2010). "Predictive biomarker validation in practice: lessons from real trials". Clin Trials. 7 (5): 567–73. doi:10.1177/1740774510368574. PMC 3913192. PMID 20392785.
Pharoah PD, Caldas C (November 2010). "Genetics: How to validate a breast cancer prognostic signature". Nat Rev Clin Oncol. 7 (11): 615–6. doi:10.1038/nrclinonc.2010.142. PMID 20981123. S2CID 32411967.
Ross, J. S.; Hatzis, C.; Symmans, W. F.; Pusztai, L.; Hortobagyi, G. N. (2008). "Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer". The Oncologist. 13 (5): 477–493. doi:10.1634/theoncologist.2007-0248. PMID 18515733. S2CID 19435207.
Albain, K. S.; Paik, S.; Van't Veer, L. (2009). "Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays". The Breast. 18: S141–S145. doi:10.1016/S0960-9776(09)70290-5. PMID 19914534.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. (August 2006). "Concordance among gene-expression-based predictors for breast cancer". New England Journal of Medicine. 355 (6): 560–569. doi:10.1056/NEJMoa052933. PMID 16899776.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. (((American Society of Clinical Oncology))) (November 2007). "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer". Journal of Clinical Oncology. 25 (33): 5287–5312. doi:10.1200/JCO.2007.14.2364. PMC 2793754. PMID 17954709.
Filho, O. M.; Ignatiadis, M.; Sotiriou, C. (2011). "Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis". Critical Reviews in Oncology/Hematology. 77 (1): 20–29. doi:10.1016/j.critrevonc.2010.01.011. PMID 20138540.
Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. (October 2005). "Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer". Journal of Clinical Oncology. 23 (29): 7265–7277. doi:10.1200/JCO.2005.02.0818. PMID 16145055.
Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, et al. (November 2010). "Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers". Cancer. 116 (22): 5161–5167. doi:10.1002/cncr.25269. PMID 20665886.
Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, et al. (April 2010). "Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection". Journal of Clinical Oncology. 28 (10): 1671–1676. doi:10.1200/JCO.2008.20.2119. PMID 20065191.
Albanell, J.; González, A.; Ruiz-Borrego, M.; Alba, E.; García-Saenz, J. A.; Corominas, J. M.; Burgues, O.; Furio, V.; Rojo, A.; Palacios, J.; Bermejo, B.; Martínez-García, M.; Limon, M. L.; Muñoz, A. S.; Martín, M.; Tusquets, I.; Rojo, F.; Colomer, R.; Faull, I.; Lluch, A. (2011). "Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer". Annals of Oncology. 23 (3): 625–631. doi:10.1093/annonc/mdr278. hdl:10630/29523. PMID 21652577.
MacGrogan G, Rudolph P, Mascarel I, Mauriac L, Durand M, Avril A, et al. (August 2003). "DNA topoisomerase II alfa expression and the response to primary chemotherapy in breast cancer". British Journal of Cancer. 89 (4): 666–671. doi:10.1038/sj.bjc.6601185. PMC 2376904. PMID 12915875.
Alvarez, R. H.; Valero, V.; Hortobagyi, G. N. (2010). "Emerging Targeted Therapies for Breast Cancer". Journal of Clinical Oncology. 28 (20): 3366–3379. doi:10.1200/JCO.2009.25.4011. PMID 20530283.
Issaeva N, Thomas HD, Djureinovic T, Djurenovic T, Jaspers JE, Stoimenov I, et al. (August 2010). "6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance". Cancer Research. 70 (15): 6268–6276. doi:10.1158/0008-5472.CAN-09-3416. PMC 2913123. PMID 20631063. Correction published at Correction: 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance Cancer Res 2010 October 1;70:7734
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. (June 2009). "Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer". Journal of Clinical Oncology. 27 (16): 2630–2637. doi:10.1200/JCO.2008.18.8391. PMID 19380449.
D'Anello L, Sansone P, Storci G, Mitrugno V, D'Uva G, Chieco P, et al. (November 2010). "Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells". Molecular Cancer. 9 300. doi:10.1186/1476-4598-9-300. PMC 3002335. PMID 21092249.
Liu, C. -C.; Prior, J.; Piwnica-Worms, D.; Bu, G. (2010). "LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy". Proceedings of the National Academy of Sciences. 107 (11): 5136–5141. Bibcode:2010PNAS..107.5136L. doi:10.1073/pnas.0911220107. PMC 2841938. PMID 20194742.
Ruiter R, Bijl MJ, van Schaik RH, Berns EM, Hofman A, Coebergh JW, et al. (October 2010). "CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen". Pharmacogenomics. 11 (10): 1367–1375. doi:10.2217/pgs.10.112. PMID 21047200.
Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjöld B, Stål O (2010). "Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer". Breast Cancer Research. 12 (4) R53: 206. doi:10.1186/bcr2612. PMC 2949642. PMID 20649975.
"Study sheds new light on tamoxifen resistance". CORDIS : News. 13 November 2008. Archived from the original on 20 February 2009. Retrieved 14 November 2008.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. (December 2008). "Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen". Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.
Mc Ilroy M, Fleming FJ, Buggy Y, Hill AD, Young LS (December 2006). "Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence". Endocr. Relat. Cancer. 13 (4): 1135–45. doi:10.1677/erc.1.01222. PMID 17158759.
Spears M, Bartlett J (June 2009). "The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer". Expert Opin. Ther. Targets. 13 (6): 665–74. doi:10.1517/14728220902911509. PMID 19456271. S2CID 39034059.
Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. (February 2001). "Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer". Journal of Clinical Oncology. 19 (4): 980–991. doi:10.1200/JCO.2001.19.4.980. PMID 11181660.
Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. (April 2005). "Population-based validation of the prognostic model ADJUVANT! for early breast cancer". Journal of Clinical Oncology. 23 (12): 2716–2725. doi:10.1200/JCO.2005.06.178. PMID 15837986. S2CID 27080534.
Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, et al. (November 2009). "Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study". Lancet Oncology. 10 (11): 1070–1076. doi:10.1016/S1470-2045(09)70254-2. PMID 19801202.
Campbell HE, Taylor MA, Harris AL, Gray AM (October 2009). "An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom". Br. J. Cancer. 101 (7): 1074–84. doi:10.1038/sj.bjc.6605283. PMC 2768087. PMID 19724274.
Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. (2010). "PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer". Breast Cancer Research. 12 (1) R1. doi:10.1186/bcr2464. PMC 2880419. PMID 20053270.
Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. (August 2010). "BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received". British Journal of Cancer. 103 (5): 668–75. doi:10.1038/sj.bjc.6605736. PMC 2938244. PMID 20664598.
Silverstein Melvin J., Lagios Michael D. (2010). "Choosing Treatment for Patients With Ductal Carcinoma In Situ: Fine Tuning the University of Southern California/Van Nuys Prognostic Index". J Natl Cancer Inst Monogr. 2010 (41): 193–196. doi:10.1093/jncimonographs/lgq040. PMC 5161065. PMID 20956828.

ncbi.nlm.nih.gov

Giordano SH, Hortobagyi GN (2003). "Inflammatory breast cancer: Clinical progress and the main problems that must be addressed". Breast Cancer Res. 5 (6) 284: 284–8. doi:10.1186/bcr608. PMC 314400. PMID 14580242.
Ductal carcinoma in situ: 99% - Kerlikowske, K (2010). "Epidemiology of ductal carcinoma in situ". Journal of the National Cancer Institute. Monographs. 2010 (41): 139–41. doi:10.1093/jncimonographs/lgq027. PMC 5161058. PMID 20956818.
Lobular carcinoma in situ: 97% - Xie, Ze-Ming; Sun, Jian; Hu, Zhe-Yu; Wu, Yao-Pan; Liu, Peng; Tang, Jun; Xiao, Xiang-Sheng; Wei, Wei-Dong; Wang, Xi; Xie, Xiao-Ming; Yang, Ming-Tian (2017). "Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy". European Journal of Cancer. 82: 6–15. doi:10.1016/j.ejca.2017.05.030. ISSN 0959-8049. PMID 28646773.
NOTE: Number really refers to invasive ductal carcinoma, despite title. Arpino G, Bardou VJ, Clark GM, Elledge RM (2004). "Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome". Breast Cancer Res. 6 (3) R149: R149–56. doi:10.1186/bcr767. PMC 400666. PMID 15084238.
Evans, A. (2004). "Ductal carcinoma in situ (DCIS): are we overdetecting it?". Breast Cancer Research. 6 (Suppl 1) P23: 23. doi:10.1186/bcr842. PMC 3300383. [1] Archived 8 July 2011 at the Wayback Machine
Bloom, H.J.; Richardson, W.W. (1957). "Histological grading and prognosis in breast cancer; A study of 1409 cases of which 359 have been followed for 15 years". British Journal of Cancer. 11 (3): 359–77. doi:10.1038/bjc.1957.43. PMC 2073885. PMID 13499785.
Originally copied from Fadi M. Alkabban; Troy Ferguson (2021). "Breast Cancer". Cancer, Breast. StatPearls. PMID 29493913. Archived from the original on 24 December 2020. Retrieved 4 October 2019 – via National Center for Biotechnology Information. Last Update: 4 June 2019. Creative Commons Attribution 4.0 International License Archived 21 November 2015 at the Wayback Machine
Data from: Mangone L; Marinelli F; Bisceglia I; Braghiroli MB; Damato A; Pinto C (2022). "Five-year relative survival by stage of breast and colon cancers in northern Italy". Front Oncol. 12 982461. doi:10.3389/fonc.2022.982461. PMC 9659859. PMID 36387150.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. (July 2011). "Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies". Journal of Clinical Investigation. 121 (7): 2750–2767. doi:10.1172/JCI45014. PMC 3127435. PMID 21633166.
Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, et al. (2011). "Androgen receptor expression and breast cancer survival in postmenopausal women". Clinical Cancer Research. 17 (7): 1867–1874. doi:10.1158/1078-0432.CCR-10-2021. PMC 3076683. PMID 21325075.
Prat, A.; Perou, C. M. (2011). "Deconstructing the molecular portraits of breast cancer". Molecular Oncology. 5 (1): 5–23. doi:10.1016/j.molonc.2010.11.003. PMC 5528267. PMID 21147047.
Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, et al. (February 2012). "Breast Cancer Special Feature: Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells". Proceedings of the National Academy of Sciences. 109 (8): 2778–2783. doi:10.1073/pnas.1018862108. PMC 3286979. PMID 21633010.
Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. (April 2012). "Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse". Breast Cancer Research and Treatment. 132 (2): 523–535. doi:10.1007/s10549-011-1619-7. PMC 3303043. PMID 21671017.
Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, et al. (2010). "Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics". Breast Cancer Research. 12 (3) R42. doi:10.1186/bcr2596. PMC 2917037. PMID 20576095.
Mandrekar SJ, Sargent DJ (October 2010). "Predictive biomarker validation in practice: lessons from real trials". Clin Trials. 7 (5): 567–73. doi:10.1177/1740774510368574. PMC 3913192. PMID 20392785.
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. (((American Society of Clinical Oncology))) (November 2007). "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer". Journal of Clinical Oncology. 25 (33): 5287–5312. doi:10.1200/JCO.2007.14.2364. PMC 2793754. PMID 17954709.
MacGrogan G, Rudolph P, Mascarel I, Mauriac L, Durand M, Avril A, et al. (August 2003). "DNA topoisomerase II alfa expression and the response to primary chemotherapy in breast cancer". British Journal of Cancer. 89 (4): 666–671. doi:10.1038/sj.bjc.6601185. PMC 2376904. PMID 12915875.
Issaeva N, Thomas HD, Djureinovic T, Djurenovic T, Jaspers JE, Stoimenov I, et al. (August 2010). "6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance". Cancer Research. 70 (15): 6268–6276. doi:10.1158/0008-5472.CAN-09-3416. PMC 2913123. PMID 20631063. Correction published at Correction: 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance Cancer Res 2010 October 1;70:7734
D'Anello L, Sansone P, Storci G, Mitrugno V, D'Uva G, Chieco P, et al. (November 2010). "Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells". Molecular Cancer. 9 300. doi:10.1186/1476-4598-9-300. PMC 3002335. PMID 21092249.
Liu, C. -C.; Prior, J.; Piwnica-Worms, D.; Bu, G. (2010). "LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy". Proceedings of the National Academy of Sciences. 107 (11): 5136–5141. Bibcode:2010PNAS..107.5136L. doi:10.1073/pnas.0911220107. PMC 2841938. PMID 20194742.
Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjöld B, Stål O (2010). "Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer". Breast Cancer Research. 12 (4) R53: 206. doi:10.1186/bcr2612. PMC 2949642. PMID 20649975.
"Study sheds new light on tamoxifen resistance". CORDIS : News. 13 November 2008. Archived from the original on 20 February 2009. Retrieved 14 November 2008.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. (December 2008). "Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen". Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.
Campbell HE, Taylor MA, Harris AL, Gray AM (October 2009). "An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom". Br. J. Cancer. 101 (7): 1074–84. doi:10.1038/sj.bjc.6605283. PMC 2768087. PMID 19724274.
Wishart GC, Azzato EM, Greenberg DC, Rashbass J, Kearins O, Lawrence G, et al. (2010). "PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer". Breast Cancer Research. 12 (1) R1. doi:10.1186/bcr2464. PMC 2880419. PMID 20053270.
Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. (August 2010). "BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received". British Journal of Cancer. 103 (5): 668–75. doi:10.1038/sj.bjc.6605736. PMC 2938244. PMID 20664598.
Silverstein Melvin J., Lagios Michael D. (2010). "Choosing Treatment for Patients With Ductal Carcinoma In Situ: Fine Tuning the University of Southern California/Van Nuys Prognostic Index". J Natl Cancer Inst Monogr. 2010 (41): 193–196. doi:10.1093/jncimonographs/lgq040. PMC 5161065. PMID 20956828.

nmcancercenter.org (Global: low place; English: low place)

New Mexico OncologyHematology Consultants, Ltd. Copyright held by CancerConsultants Breast Cancer Information Center. European Study Reports that Oncotype DX Influences Breast Cancer Treatment Decisions. Posted 2010 October 17, accessioned 2010 Dec 19 and 2, 011 July 3 at http://nmcancercenter.org/european-study-reports-that-oncotype-dx%C2%AE-influences-breast-cancer-treatment-decisions/ Archived 28 March 2012 at the Wayback Machine

rsna.org (Global: 9,820^th place; English: 6,888^th place)

radiographics.rsna.org

Scatarige JC, Boxen I, Smathers RL (September 1990). "Internal mammary lymphadenopathy: imaging of a vital lymphatic pathway in breast cancer". Radiographics. 10 (5): 857–70. doi:10.1148/radiographics.10.5.2217975. PMID 2217975. available as full text article with multiple images at http://radiographics.rsna.org/content/10/5/857.full.pdf

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Elston, CW; Ellis, IO (1991). "Pathologic prognostic factors in breast cancer. I. The value of histological grades in breast cancer. Experience from a large study with long-term follow-up". Histopathology. 19 (5): 403–10. doi:10.1111/j.1365-2559.1991.tb00229.x. PMID 1757079. S2CID 17622089. "Republished". Histopathology. 41: 154–161. 2002. doi:10.1046/j.1365-2559.2002.14892.x. S2CID 208083532.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. (October 2005). "Trastuzumab plus adjuvant chemotherapy for operable HER2+ breast cancer". The New England Journal of Medicine. 353 (16): 1673–1684. doi:10.1056/NEJMoa052122. PMID 16236738. S2CID 9534884.
Geyer, F. C.; Marchiò, C.; Reis-Filho, J. S. (2009). "The role of molecular analysis in breast cancer". Pathology. 41 (1): 77–88. doi:10.1080/00313020802563536. PMID 19089743. S2CID 39374813.
Ross, J. S. (2009). "Multigene Classifiers, Prognostic Factors, and Predictors of Breast Cancer Clinical Outcome". Advances in Anatomic Pathology. 16 (4): 204–215. doi:10.1097/PAP.0b013e3181a9d4bf. PMID 19546609. S2CID 37465636.
Tsang, Julia Y.S.; Tse, Gary M. (2020). "Molecular Classification of Breast Cancer". Advances in Anatomic Pathology. 27 (1): 27–35. doi:10.1097/PAP.0000000000000232. ISSN 1072-4109. PMID 31045583. S2CID 143423297.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. (August 2000). "Molecular portraits of human breast tumours". Nature. 406 (6797): 747–752. Bibcode:2000Natur.406..747P. doi:10.1038/35021093. PMID 10963602. S2CID 1280204.
Nagasaki K, Miki Y (2006). "Gene expression profiling of breast cancer". Breast Cancer. 13 (1): 2–7. doi:10.2325/jbcs.13.2. PMID 16518056. S2CID 6255927.
Normanno N, De Luca A, Carotenuto P, Lamura L, Oliva I, D'Alessio A (2009). "Prognostic applications of gene expression signatures in breast cancer". Oncology. 77 (Suppl 1): 2–8. doi:10.1159/000258489. PMID 20130425. S2CID 21011879.
Pharoah PD, Caldas C (November 2010). "Genetics: How to validate a breast cancer prognostic signature". Nat Rev Clin Oncol. 7 (11): 615–6. doi:10.1038/nrclinonc.2010.142. PMID 20981123. S2CID 32411967.
Ross, J. S.; Hatzis, C.; Symmans, W. F.; Pusztai, L.; Hortobagyi, G. N. (2008). "Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer". The Oncologist. 13 (5): 477–493. doi:10.1634/theoncologist.2007-0248. PMID 18515733. S2CID 19435207.
Spears M, Bartlett J (June 2009). "The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer". Expert Opin. Ther. Targets. 13 (6): 665–74. doi:10.1517/14728220902911509. PMID 19456271. S2CID 39034059.
Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, et al. (April 2005). "Population-based validation of the prognostic model ADJUVANT! for early breast cancer". Journal of Clinical Oncology. 23 (12): 2716–2725. doi:10.1200/JCO.2005.06.178. PMID 15837986. S2CID 27080534.

stanford.edu (Global: 179^th place; English: 183^rd place)

surgpathcriteria.stanford.edu

"Medullary Carcinoma of the Breast". Stanford Medicine. Archived from the original on 8 September 2020. Retrieved 31 December 2020.
"Metaplastic Carcinoma of the Breast". Stanford Medicine. Archived from the original on 8 September 2020. Retrieved 31 December 2020.
"Infiltrating Ductal Carcinoma of the Breast (Carcinoma of No Special Type)". Stanford University School of Medicine. Archived from the original on 11 September 2019. Retrieved 2 October 2019.

unc.edu (Global: 1,538^th place; English: 1,042^nd place)

cdr.lib.unc.edu

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. (August 2000). "Molecular portraits of human breast tumours". Nature. 406 (6797): 747–752. Bibcode:2000Natur.406..747P. doi:10.1038/35021093. PMID 10963602. S2CID 1280204.

web.archive.org (Global: 1^st place; English: 1^st place)

Merck Manual, Professional Edition Archived 1 July 2010 at the Wayback Machine, Ch. 253, Breast Cancer.
"FDA Approves First Targeted Therapy for HER2-Low Breast Cancer". U.S. Food and Drug Administration (FDA) (Press release). 5 August 2022. Archived from the original on 6 August 2022. Retrieved 5 August 2022. This article incorporates text from this source, which is in the public domain.
Page 1084 Archived 6 August 2022 at the Wayback Machine in: Robbins, Stanley (2010). Robbins and Cotran pathologic basis of disease. Philadelphia, PA: Saunders/Elsevier. ISBN 978-1-4377-2182-9. OCLC 489074868.
Percentage values are from United States statistics 2004. Subtype specific incidences are taken from Table 6 Archived 23 February 2013 at archive.today (invasive) and Table 3 Archived 23 February 2013 at archive.today (in situ) from Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC (June 2009). "The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999–2004". Cancer Epidemiol. Biomarkers Prev. 18 (6): 1763–9. doi:10.1158/1055-9965.EPI-08-1082. PMID 19454615.. These are divided by total breast cancer incidence (211,300 invasive and 55,700 in situ cases) as reported from Breast Cancer Facts & Figures 2003–2004 "ACS :: Breast Cancer Facts & Figures 2003-2004". Archived from the original on 15 April 2009. Retrieved 15 June 2010.
Evans, A. (2004). "Ductal carcinoma in situ (DCIS): are we overdetecting it?". Breast Cancer Research. 6 (Suppl 1) P23: 23. doi:10.1186/bcr842. PMC 3300383. [1] Archived 8 July 2011 at the Wayback Machine
Oudai Hassan. "What is the Nottingham combined histologic grade (modified Scarff-Bloom-Richardson grade) system for breast tumors?". Medscape. Archived from the original on 30 November 2020. Retrieved 2 October 2019. Updated: 20 March 2019
"Medullary Carcinoma of the Breast". Stanford Medicine. Archived from the original on 8 September 2020. Retrieved 31 December 2020.
"Metaplastic Carcinoma of the Breast". Stanford Medicine. Archived from the original on 8 September 2020. Retrieved 31 December 2020.
"Infiltrating Ductal Carcinoma of the Breast (Carcinoma of No Special Type)". Stanford University School of Medicine. Archived from the original on 11 September 2019. Retrieved 2 October 2019.
What is Cancer Staging? American Joint Committee on Cancer 2010 May 5.http://www.cancerstaging.org/mission/whatis.html Archived 27 August 2013 at the Wayback Machine
National Cancer Institute. Stage Information for Breast Cancer.http://www.cancer.gov/cancertopics/pdq/treatment/breast/healthprofessional/page3 Archived 8 June 2011 at the Wayback Machine
Originally copied from Fadi M. Alkabban; Troy Ferguson (2021). "Breast Cancer". Cancer, Breast. StatPearls. PMID 29493913. Archived from the original on 24 December 2020. Retrieved 4 October 2019 – via National Center for Biotechnology Information. Last Update: 4 June 2019. Creative Commons Attribution 4.0 International License Archived 21 November 2015 at the Wayback Machine
Joseph A Sparano, MD (6 October 2021). "Breast Cancer Staging". medscape. Archived from the original on 13 September 2020. Retrieved 21 August 2020. Updated: 8 June 2019
American Joint Committee on Cancer. Past Editions of the AJCC Cancer Staging Manual available at "American Joint Committee on Cancer: Publications & Electronic Products: Past Editions of the AJCC Cancer Staging Manual". Archived from the original on 6 January 2011. Retrieved 3 January 2011.
AJCC Cancer Staging Manual, 7th edition, updated Cancer Staging Posters.http://www.cancerstaging.org/staging/posters/breast8.5x11.pdf Archived 26 June 2011 at the Wayback Machine
AJCC Cancer Staging Manual 6th edition; Chapter 25; Breast Cancer – original pages 223-240 http://www.cancerstaging.org/products/csmanual6ed-4.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 5th edition; Chapter 25; Breast Cancer – original pages 171-180 http://www.cancerstaging.org/products/csmanual5ed_4.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 4th edition; Chapter 25; Breast Cancer – original pages 149-154 http://www.cancerstaging.org/products/csmanual4ed_2.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 3rd edition; 1988; Chapter 23; Breast Cancer-original pages 145-150 http://www.cancerstaging.org/products/csmanual3ed_2.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 2nd edition; 1983; Chapter 21; Breast Cancer-original pages 127-134 http://www.cancerstaging.org/products/csmanual2ed.pdf Archived 28 September 2011 at the Wayback Machine
AJCC Cancer Staging Manual 1977; Chapter 12; Breast Cancer-original pages 101-108 http://www.cancerstaging.org/products/csmanual1ed.pdf Archived 28 September 2011 at the Wayback Machine
"National Comprehensive Cancer Network (NCCN) guidelines, Breast Cancer Version 2.2011" (PDF). Archived (PDF) from the original on 24 March 2009. Retrieved 3 July 2011.
Sotirou Christos, Pusztai Lajos (2009). "Molecular origin of cancer: gene-expression signatures in breast cancer". The New England Journal of Medicine. 360 (8): 790–800. doi:10.1056/NEJMra0801289. PMID 19228622. Archived from the original on 5 January 2010. Retrieved 16 June 2010.
"Understanding and Treating Triple-Negative Breast Cancer". Cancer Network. Archived from the original on 9 June 2010. Retrieved 8 May 2010.
Armen Hareyanon. MapQuant Dx Genomic Grade Test Identifies Breast Cancer Patients. 2 June 2008 http://www.emaxhealth.com/98/22731.html Archived 29 September 2011 at the Wayback Machine
"Select your country: Qiagen Marseille" (PDF). ipsogen.com. Archived from the original (PDF) on 26 March 2012. Retrieved 12 December 2015.
New Mexico OncologyHematology Consultants, Ltd. Copyright held by CancerConsultants Breast Cancer Information Center. European Study Reports that Oncotype DX Influences Breast Cancer Treatment Decisions. Posted 2010 October 17, accessioned 2010 Dec 19 and 2, 011 July 3 at http://nmcancercenter.org/european-study-reports-that-oncotype-dx%C2%AE-influences-breast-cancer-treatment-decisions/ Archived 28 March 2012 at the Wayback Machine
Tice JA. The 70-Gene Signature (MammaPrint) as a Guide for the Management of Early Stage Breast Cancer. California Technology Assessment Forum. 2010 June 2nd. Full text accessioned 2010 Dec 19 at http://www.ctaf.org/content/assessments/detail/?id=1178 Archived 25 July 2011 at the Wayback Machine
NCI Cancer Bulletin FDA Update 2007 February 14, Volume 4, Number 7 as Retrieved 17 October 2010 at http://www.cancer.gov/aboutnci/ncicancerbulletin/archive/2007/021407/page5 Archived 22 December 2010 at the Wayback Machine
The mission of Agendia. Agendia web isite.http://www.agendia.com/pages/mission/86.php Archived 23 November 2013 at the Wayback Machine
Ordering Symphony is a simple process. Agendia web site.http://www.agendia.com/pages/ordering_symphony/38.php Archived 5 June 2011 at the Wayback Machine
MammaPrint Patient Eligibility Internationally (Outside of the USA) http://www.agendia.com/pages/patient_eligibility_internationally/317.php Archived 5 June 2011 at the Wayback Machine
Introducing BluePrint: A Molecular Subtyping Profile for Breast Cancer. Agendia web site.http://www.agendia.com/pages/blueprint/324.php Archived 3 September 2011 at the Wayback Machine
Gene Review TOP2A – topoisomerase (DNA) II alpha 170kDa Homo sapiens as Retrieved 18 October 2010 [2]
Rae, JM; Drury, S; Hayes, DF; et al. (9 December 2010). "Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial. 33rd Annual San Antonio Breast Cancer Symposium (SABCS): abstract S1-7". Archived from the original on 11 August 2011. Retrieved 17 December 2010.
Leyland-Jones, B; Regan, MM; Bouzyk, M; et al. (9 December 2010). "Outcome According to CYP2D6 Genotype among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial. 33rd Annual San Antonio Breast Cancer Symposium (SABCS): abstract S1-8". Archived from the original on 7 July 2011. Retrieved 17 December 2010.
"Study sheds new light on tamoxifen resistance". CORDIS : News. 13 November 2008. Archived from the original on 20 February 2009. Retrieved 14 November 2008.
Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. (December 2008). "Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen". Nature. 456 (7222): 663–666. Bibcode:2008Natur.456..663H. doi:10.1038/nature07483. PMC 2920208. PMID 19005469.

wikimedia.org (Global: low place; English: low place)

commons.wikimedia.org

References for pie chart is located at Image description page in commons

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Page 1084 Archived 6 August 2022 at the Wayback Machine in: Robbins, Stanley (2010). Robbins and Cotran pathologic basis of disease. Philadelphia, PA: Saunders/Elsevier. ISBN 978-1-4377-2182-9. OCLC 489074868.
Ductal carcinoma in situ: 99% - Kerlikowske, K (2010). "Epidemiology of ductal carcinoma in situ". Journal of the National Cancer Institute. Monographs. 2010 (41): 139–41. doi:10.1093/jncimonographs/lgq027. PMC 5161058. PMID 20956818.
Lobular carcinoma in situ: 97% - Xie, Ze-Ming; Sun, Jian; Hu, Zhe-Yu; Wu, Yao-Pan; Liu, Peng; Tang, Jun; Xiao, Xiang-Sheng; Wei, Wei-Dong; Wang, Xi; Xie, Xiao-Ming; Yang, Ming-Tian (2017). "Survival outcomes of patients with lobular carcinoma in situ who underwent bilateral mastectomy or partial mastectomy". European Journal of Cancer. 82: 6–15. doi:10.1016/j.ejca.2017.05.030. ISSN 0959-8049. PMID 28646773.
Pujani, Mukta; Sharma, KiranLata; Srivastava, AN; Singh, US; Bansal, Cherry (2014). "Grading systems in the cytological diagnosis of breast cancer: A review". Journal of Cancer Research and Therapeutics. 10 (4): 839–845. doi:10.4103/0973-1482.140979. ISSN 0973-1482. PMID 25579516.
Tsang, Julia Y.S.; Tse, Gary M. (2020). "Molecular Classification of Breast Cancer". Advances in Anatomic Pathology. 27 (1): 27–35. doi:10.1097/PAP.0000000000000232. ISSN 1072-4109. PMID 31045583. S2CID 143423297.

Breast cancer classification (English Wikipedia)

aacrjournals.org (Global: 8,869th place; English: 8,487th place)

cebp.aacrjournals.org

abstracts2view.com (Global: low place; English: low place)

agendia.com (Global: low place; English: low place)

archive.org (Global: 6th place; English: 6th place)

archive.today (Global: 14th place; English: 14th place)

books.google.com (Global: 3rd place; English: 3rd place)

breast-cancer-research.com (Global: low place; English: low place)

cancer.gov (Global: 1,684th place; English: 1,350th place)

cancer.org (Global: 3,680th place; English: 2,918th place)

cancernetwork.com (Global: low place; English: low place)

cancerstaging.org (Global: low place; English: low place)

creativecommons.org (Global: 1,010th place; English: 612th place)

ctaf.org (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

emaxhealth.com (Global: low place; English: low place)

europa.eu (Global: 68th place; English: 117th place)

cordis.europa.eu

fda.gov (Global: 447th place; English: 338th place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

ipsogen.com (Global: low place; English: low place)

medscape.com (Global: 719th place; English: 636th place)

medscape.com

emedicine.medscape.com

merck.com (Global: 6,464th place; English: 5,671st place)

nccn.org (Global: low place; English: low place)

nejm.org (Global: 2,374th place; English: 6,027th place)

content.nejm.org

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nmcancercenter.org (Global: low place; English: low place)

rsna.org (Global: 9,820th place; English: 6,888th place)

radiographics.rsna.org

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

stanford.edu (Global: 179th place; English: 183rd place)

surgpathcriteria.stanford.edu

unc.edu (Global: 1,538th place; English: 1,042nd place)

cdr.lib.unc.edu

web.archive.org (Global: 1st place; English: 1st place)

wikimedia.org (Global: low place; English: low place)

commons.wikimedia.org

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

aacrjournals.org (Global: 8,869^th place; English: 8,487^th place)

archive.org (Global: 6^th place; English: 6^th place)

archive.today (Global: 14^th place; English: 14^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

cancer.gov (Global: 1,684^th place; English: 1,350^th place)

cancer.org (Global: 3,680^th place; English: 2,918^th place)

creativecommons.org (Global: 1,010^th place; English: 612^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

medscape.com (Global: 719^th place; English: 636^th place)

merck.com (Global: 6,464^th place; English: 5,671^st place)

nejm.org (Global: 2,374^th place; English: 6,027^th place)

nih.gov (Global: 4^th place; English: 4^th place)

rsna.org (Global: 9,820^th place; English: 6,888^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

stanford.edu (Global: 179^th place; English: 183^rd place)

unc.edu (Global: 1,538^th place; English: 1,042^nd place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 5^th place; English: 5^th place)